another class action in the verks? Management not disclosing enough about trial developments(ODD EU), milestone payment timelines and fwd looking statements on earning potential. Plus an irresponsible acquisition intention which placed a weighted noose on SP after the 8K in Aug. and again in Dec. Triggered the entire China syndrome move on the world market and caused Yellen to stop hiking on the interest rate trail singing happy trails.
INO has had a much larger pop than CERS. Any reasons why?
2015's SP action was the same as 2014 without any premium gained on all the +ve news developments we've had since the FDA hold. True they keep kicking the timeline can down the road but when the SP can barely hold $3 two years after being in the $5's is not only questionable but actionable. To deny this as fact is denying the truth regardless of who pays your harassing MO. How could any LT investor possibly be happy with such a lagger given the growth potential?
Jack be nibble.... think he doth protest too much.
Doesn't Ohio become part of the Canadian тундра every winter?
Irish's posts are usually followed by a major drop in SP. I followed her charge into the FDA hold on March 2014 expecting a much larger Mayo clinical trial study to start by June only to lose 85% of my investment. She later admitted to not personally investing in GERN herself opting for having everything tied up in Florida real estate instead. What does that tell you. Here we are at the same fork in the road two years later waiting for what appears to be MF results by June. Only this time Sp is $2/share lower. Trust Irish with your investment advice at your own peril.
I've never pumped INCY nor their drug Jakafi, although was told by a leading American oncologist it works well for symptomatic relief. IMET is going for the ceiling with CR's and PR's much of which have been confused by the likes of these pseudo experts throwing around terminology such as clinical/complete remissions/responses which all have different meanings.
Had I gone with my gut instinct and stayed out the first time I exited after the 2014 JP Morgan "confusing mixed signal CC" I would have preserved my capital. As iyt stands any potential break even was wiped away in the last month's 40% correction. Irish should not be posting on an "investment" forum....she's been toxic to realistic SP time frame expectations. 2 years out now and 45% down. INCY has not slowed GERN's IMET development down. The company itself has been totally responsible. The class action isn't against INCY, it's against GERN's current board for not disclosing adequately possible concerns the FDA might have with IMET just like now where share holders are in the dark wrt to certain contractual hidden clauses. What's behind that magic curtain is not the Wizzard of Oz nor a pot of gold it might be a shocking reality for shareholders/
that is a direct lie Irish. You said John 'chose' to stop infusions not that he was forced off it. Change your story for the right effect. He resumed when his CR status diminished but by choice. NOW LETS BLAME THE INCY LOBBY
It took him 6 months after much criticism to actual come out and say that during our last CC. WHY SO LONG?
|Irish. then why do you never challenge our company for more transparency. 3 years later and investors are still in the dark.
nothing "morale' about leading investors on for 2 years pretending to have an "inside" scoop. She's been DEAD wrong with IMET's development and the time lines we have.
this sage advice coming from the brain fart that sold his AST shares the minute they were distributed in the $3`s
....what about my low priced GERON shares? Great bargain AGAIN down here barely holding $3
ask Irish; she was my shrink whilst growing up as a child pup. Did a great job 'eh'?
GERN never ran the IMET pipeline; it was contracted out to the MAYO. When it was time to expand the trial for phase 3 Scarlet negotiated a deal with Janssen to do it. Why on earth do you think a 65 year old CEO would want to buy another upstart if his whole curriclim vitae has been based on farming out or selling out drug pipelines? It's a stupid excuse to keep placing the blame elsewhere. The buck stops with the CEO and the 2-3 investment representatives that do ever attend GERN's public conference calls.(never heard more than a few hands clapping afterwards). Why was Scarlet sandbagging with the acquisition since June and then did an about face public announcement at his last CC saying he would NOT pursue an acquisition till IMET was further developed with royalty payments. And where are the $65 mil milestone payments for 2 new trial infusions from last fall and Dec?
will GERN announce a PP saying they are going ahead with some upstart acquisition causing another 40% haircut or will we get Joanie's long awaited short squeeze (they've added back on) with some +ve update from Janssen? Curious critters want to know.